The p53 tumour suppressor protein is tightly regulated by protein-protein association, protein turnover and a variety of post-translational modi®cations. Multisite phosphorylation plays a major role in activating and in ®nely tuning p53 function. The proline rich domain of murine p53 is a substrate for phosphorylation, in vitro and in cultured cells, by the p42 ERK2 and p44 ERK1 mitogenactivated protein (MAP) kinases. However, to date there have been no reports of attempts to determine whether p53 from any other species is a substrate for MAP kinase. In this paper we con®rm that murine p53 is targeted by recombinant MAP kinase and by MAP kinases in extracts of both murine and human cells. In contrast, human p53 is not a substrate for recombinant MAP kinase nor are there any detectable levels of protein kinase activity in stimulated human cell extracts which phosphorylate the proline rich domain of human p53 in vitro. Finally, although stimulation of murine ®broblasts with o-tetradecanolylphorbol 13-acetate (TPA), an indirect activator of the MAP kinase pathway, leads to site-speci®c phosphorylation of murine p53, similar treatment of human ®broblasts and epithelial cells showed no signi®cant changes in the phosphorylation pattern. These data are consistent with accumulating evidence that signi®cant species-dependent dierences exist in the post-translational modi®cation of p53.
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Keywords: p53; ERK; MAP kinase; phosphorylation The p53 tumour suppressor protein is a short-lived, latent transcription factor which is activated and stabilized in response to a wide range of cellular stresses including DNA damage, hypoxia, mitotic spindle damage and activated oncogenes; (for recent reviews see Agarwal et al., 1998; Prives and Hall, 1999) . Activated p53 acts as a checkpoint which coordinates a shift in the pattern of gene expression involving the induction of genes which promote growth arrest or apoptosis and the repression of genes which stimulate growth or block apoptosis. Loss of p53 function through mutation is a common occurrence in the development of a wide range of human tumours (Hollstein et al., 1996) . In animal models, the absence of p53 permits the occurrence of numerous genetic alterations, including gene ampli®cation and abnormal chromosome numbers, and leads to the development of a variety of tumours in young adults (Donehower et al., 1992; Fukasawa et al., 1997; Livingstone et al., 1992; Yin et al., 1992) .
At the protein level the regulation of p53 is complex and involves interdependent control by protein-protein association, protein turnover and post-translational modi®cation. p53 has been shown to be phosphorylated by a range of dierent protein kinases (Giaccia and Kastan, 1998; Meek, 1997 Meek, , 1998 Prives and Hall, 1999) , including the p42 ERK2 and p44 ERK1 mitogenactivated protein kinases (Milne et al., 1994) . The mitogen-activated protein (MAP) kinases (also known as extracellular signal regulated kinases [ERKs] ) are a family of protein kinases which are activated through protein kinase signalling cascades in response to a wide range of growth factors and dierentiation agents (for recent reviews see Campbell et al., 1998; Robinson and Cobb, 1997) . Activated MAP kinases phosphorylate many cytoplasmic and nuclear substrates including a range of dierent transcription factors. Several protooncogene products (including Raf, Ras and Src) lie upstream of MAP kinase and expression of constitutively active MAP kinase kinase (the protein kinase immediately upstream of MAP kinase) causes transformation of cells in culture (Cowley et al., 1994; Mansour et al., 1994) . Phosphorylation of murine p53 by ERKs 1 and 2 occurs at threonines 73 and 83 (Milne et al., 1994) which lie within the proline rich domain of p53, a region which is required for p53-dependent apoptosis and Gas1-mediated growth arrest (Ruaro et al., 1997; Sakamuro et al., 1997; Venot et al., 1998; Walker and Levine, 1996) . The proline rich domain is speci®cally phosphorylated following treatment of murine ®broblasts with TPA, an indirect activator of the MAP kinase pathway, underscoring the idea that p53 and MAP kinase interact physiologically (Milne et al., 1994 (Milne et al., , 1996 . The link between p53 and MAP kinase suggested that p53 might be sensitive, at least in part, to changes in growth status or oncogene action through this interaction (Milne et al., 1994) .
Analysis of protein-and peptide-substrates have indicated that serine or threonine followed by a proline (S/T-P) constitutes the minimal consensus sequence for phosphorylation by ERK (Gonzalez et al., 1991; Songyang et al., 1996) . Moreover, a proline residue located at the 72 position relative to the target residue is strongly preferred for phosphorylation by ERK (P-X-S/T-P) whereas a proline at the 71 position (P-S/T-P) diminishes the phosphorylation reaction (Gonzalez et al., 1991; Songyang et al., 1996) . In addition to this core motif it is becoming clear that the MAP kinases utilize distinct docking sites which are thought to mediate substrate speci®city and distinguish ERK substrates from those of related enzymes such as the JNK and p38 SAP kinases (Gavin and Nebreda, 1999; Jacobs et al., 1999; Yang et al., 1998) . However, while dierent docking sites have been de®ned in select groups of MAP kinase substrates and shown to be important for substrate recognition, it is not yet clear whether there is a universal docking site(s) for all ERK substrates. Consistent with the idea that MAP kinase phosphorylates murine p53 in vivo, the sites in murine p53 phosphorylated by ERK in vitro (thr73 and thr83) match the core T-P consensus while thr83 additionally lies within a P-X-T-P motif. The P-X-T-P motif is also present at similar locations in bovine, feline and hamster p53 (Soussi and May, 1996) . Moreover, several other mammalian p53 proteins contain at least one S/T-P motif located at a similar position to the murine thr83 within the proline rich domain (Soussi and May, 1996) suggesting that the need for serine or threonine residues, possibly in the context of a phosphorylation site, is conserved among the mammals. In human p53 however, thr81 lies within a P-T-P which, in the context of synthetic peptide substrates, disfavours phosphorylation by MAP kinase (Gonzalez et al., 1991; Songyang et al., 1996) . These ®ndings call into question whether p53 proteins from species other than mouse are indeed targets for MAP kinase. Alternatively, it is possible that S/T-P motifs in positions equivalent to the P-X-T-P motif of murine p53 may be phosphorylated by a dierent but perhaps related kinase. To explore these ideas, we have analysed the phosphorylation of human p53 by recombinant ERK1 and by protein kinase activities present in extracts of human cells.
We showed previously that untagged full length murine p53 and a GST-p53 fusion protein containing the amino terminal 84 amino acids of murine p53 are each phosphorylated at threonines 73 and 83 by MAP kinase in vitro (Milne et al., 1994) . Therefore, as a Figure 1 Phosphorylation of human and murine p53 proteins (as GST-p53 fusions) by recombinant activated MAP kinase and by MCF-7 cell extracts in vitro. The glutathione S-transferase (GST)-p53 fusion proteins used as substrates are as follows: GST-ms p53 NT comprises the N-terminal 84 amino acids of murine p53 fused to the C-terminus of GST (previously designated FP221 in (Milne et al., 1995) ). ms ala73, ms ala83 and ms ala73, 83 are derivatives of GST-ms p53 NT in which threonine to alanine substitutions are present respectively at residues 73, 83 and 73 and 83 together. GST-hu p53 comprises full length human p53 fused to the C-terminus of GST. p53 kinase assays were carried out using GST-p53 fusion proteins which were immobilized on glutathione-sepharose 4B beads as described elsewhere (Milne et al., 1995) . The beads were resuspended in a total volume of 20 ml and the reactions were initiated by the addition of enzyme. Proteins were phosphorylated in vitro using 10 units of recombinant, activated MAP kinase (from Prof Sir P Cohen, Dundee) in 25 mM Tris [pH 7.5] 10 mM MgCl 2 , 0.2 mM EDTA, 0.1 mM EGTA, 1 mM NaF, 1 mM sodium orthovanadate and 20 mM [g-32 P]ATP (speci®c activity 1.48 MBq/nmol). Proteins were also phosphorylated in vitro using 10 units of recombinant DNA-activated protein kinase from Promega or 100 units of recombinant protein kinase CK1 from NEB, and in each case the reaction conditions were those recommended by the manufacturer. All reactions were incubated for 30 min at 308C and stopped by adding an equal volume of 26SDS sample buer. Reaction products were separated by SDS ± PAGE on 10 or 12.5% gels and the phosphorylated proteins visualized by autoradiography. The panels are as follows: (a) (i) The GST-p53 fusion proteins comprising the N-terminal 84 amino acids of murine p53 containing no amino acid changes (ms p53 NT), thr to ala at position 73 (ms ala73), thr to ala at position 83 (ms ala 83) or thr to ala at positions 73 and 83 (ms ala73,83) were phosphorylated in vitro by recombinant MAP kinase. (ii) The GST-full length human p53 protein was used in each case and was phosphorylated by recombinant MAP kinase (MAPK), DNA-activated protein kinase (DNA-PK) or protein kinase CK1 (CK1). The positions at which the fusion proteins migrate in SDS ± PAGE are indicated. (b) Human MCF-7 cells were maintained in 0.5% serum for 24 h. 30 min prior to harvesting, the protein kinase C-speci®c activator o-tetradecanoylphorbol 13-acetate (TPA) was added to a ®nal concentration of 160 ng/ml; an equal volume of DMSO, the solvent for the inhibitor, was added to control plates. Cells were lysed in 10 mM Tris [pH 7.5], 2 mM EDTA, 0.1 M NaCl, 50 mM NaF, 1% (v/v) IGEPAL, 1 mM benzamidine, 1.9 mg/ml aprotinin, 1 mM leupeptin, and 1 mM pepstatin. The MCF-7 cell extracts were used to phosphorylate the GST-ms p53 NT (murine p53 [i] ) and GSThu p53 proteins (human p53 [ii] ) under identical conditions. The phosphorylated proteins were detected by autoradiography following separation by SDS ± PAGE. The positions to which the substrate proteins migrated in SDS ± PAGE are indicated control for our analysis of human p53 phosphorylation by MAP kinase, the GST-murine p53 (amino acids 1 ± 84) protein (ms p53 NT) was incubated in the presence of activated ERK1 and g-32 P-labelled ATP ( Figure  1a[i] ). The data con®rmed that murine p53 is a substrate for recombinant ERK1. Substitution of thr73 by alanine (ala) resulted in a slight reduction in the level of phosphate incorporation into p53. However, substitution of thr83 (which lies within a canonical P-X-S/T-P MAP kinase phosphorylation motif) almost completely abolished MAP kinasedependent phosphorylation. A similar observation was made when both thr73 and thr83 were changed. These data are consistent with our previous suggestion that thr83 is the preferred target of MAP kinase (Milne et al., 1994) . To determine whether human p53 was also a substrate for MAP kinase in vitro, puri®ed GSThuman p53 protein was incubated in the presence of the activated ERK1 and g-32 P-labelled ATP, under identical conditions to the murine protein ( Figure  1a [ii]). There was no detectable phosphorylation of human p53 by ERK1. To eliminate the possibility that the presence of the GST tag might interfere with the p53-kinase interaction or alter the conformation of p53 in a manner which hindered access to the N-terminus of p53 by the kinase, the GST-human p53 protein was incubated in the presence of g-32 P-ATP and two other protein kinases known to phosphorylate the Nterminus of p53 in vitro. The data indicated that the p53 could be phosphorylated both by DNA-activated protein kinase and by protein kinase CK1 (casein kinase 1) con®rming that the N-terminus of p53 is accessible to modifying enzymes.
Stimulation of serum-starved C57MG cells with agents which activate MAP kinase has been shown to induce two p53 (thr73, 83) kinases which were identi®ed as ERK1 and ERK2 (Milne et al., 1994) . We have con®rmed these data and shown that neither of the protein kinase activities from the C57MG cells was able to phosphorylate human p53 (data not shown). It is possible however, that phosphorylation of the proline rich domain of human p53 is phosphorylated by a dierent, possibly related, protein kinase(s) present in human, but not murine cells. To test this idea we examined the protein kinase activities in human MCF-7 cells which, like the murine C57MG cells, are of mammary origin and express wild type p53. Figure 1b[i] (ms p53 NT) shows that MCF-7 cell extracts (maintained in 0.5% serum) contained basal levels of protein kinase activity which phosphorylated the N-terminus of murine p53; this activity was not active towards GST alone (data not shown). Treatment of the cells with DMSO (the solvent for TPA) gave a slight stimulation in p53 kinase activity. Treatment with TPA gave a signi®cant stimulation of p53 phosphorylation; moreover this phosphorylation produced a characteristic increase in the mobility of the protein in SDS gels which we previously showed occurs in response to serum-stimulated phosphorylation of the polyproline domain (Milne et al., 1995) . These data indicate that, as with the murine C57MG cells, TPAstimulated protein kinase activity towards murine p53 was present in the human MCF-7 cell extracts. Twodimensional tryptic phosphopeptide mapping ( Figure  2 ) con®rmed that the TPA-treated cell extracts gave rise to an additional phosphopeptide (Figure 3c ) not Figure 2 Phosphopeptide analysis of GST-p53 fusion proteins phosphorylated in vitro by extracts of untreated or treated MCF-7 cells. GST-msp53 NT and GST-hu p53 proteins phosphorylated by protein kinase activities in MCF-7 cell extracts (see Figure 1) were extracted, oxidized and digested with trypsin as described previously (Knippschild et al., 1997) . The samples were: GST-ms p53 NT, a ± c; GST hu p53 (e ± g). The treatments were: 0.5% serum (untreated, a, e); DMSO (the solvent for the TPA; b, f); 160 ng/ml TPA (c, g). Keys to the identity of the murine and human phosphopeptides are given in d and h respectively. The TPA-stimulated phosphopeptide in c is indicated by an arrow present in the untreated or DMSO-treated samples (Figures 2a,b respectively) . The migration properties of this novel peptide match those of the TPA-stimulated modi®cation of p53 in SV3T3 cells (Milne et al., 1994 .
When these same extracts were used to phosphorylate the GST-fusion protein containing full length human p53 (GST-hu p53) there was once again a basal activity towards the protein (Figure 1b[ii] ), which was elevated slightly in the DMSO-treated cells ( Figure  1b[ii] ). The phosphopeptide mapping data indicated that this basal activity phosphorylated predominantly C-terminal sites (Figure 2e ± g ). In contrast to the phosphorylation of the murine protein, the TPAstimulated extracts actually showed less activity towards human p53 (Figure 1b[ii] ). The phosphopeptide mapping data con®rmed that TPA stimulation did not give rise to any novel phosphopeptides (Figure 2g) .
We have shown previously that short-term stimulation of murine SV3T3 cells with the tumour promoter TPA leads to a speci®c stimulation of phosphorylation of the p53 proline rich domain with no signi®cant change in any of the other phosphorylation sites in the protein (Milne et al., 1994 (Milne et al., , 1996 . In these previous studies we used the SV40-transformed line because the high levels of p53 and extensive degree of phosphorylation of the protein (particularly at the N-terminus) permitted easy detection of phosphopeptides and unequivocal interpretation of the data. Therefore, to make our examination of the phosphorylation of human p53 comparable with the murine data, GM701 cells, an SV40-immortalized human ®broblast cell line was used. GM701 cells were labelled with 32 Porthophosphate and stimulated with TPA under the same conditions as were used for the murine analyses. The results (Figure 3) show clearly that the phosphorylation status of human p53 immunoprecipitated from GM701 cells is multisite in nature (Figure 3a ) and compares well with the p53 from the murine SV3T3 cells (Figure 3c ). However, whereas TPA stimulation of the murine cells led to a speci®c stimulation of the phosphorylation of the proline rich domain (compare Figure 3d with c) , TPA stimulation of the human cells had little eect (compare Figure 3b with a) . To rule out the possibility that the presence of SV40 might mask the eects of TPA stimulation, p53 from 32 P-labelled MCF-7 cells was also examined. Although the radioactive signal was weaker than with the GM701 cells, again no signi®cant changes were observed in the phosphorylation status of the p53 following TPA stimulation (Figure 3e These data strongly support the idea that while murine p53 is a physiological target of MAP kinase, phosphorylation of human p53 is unaected following the activation of the MAP kinase pathway.
The data we have presented in this paper con®rm previously published ®ndings that murine p53 is a substrate for MAP kinase, both in vitro and in cultured cells (Figures 1 ± 3 ; Milne et al., 1994 Milne et al., , 1996 . In contrast, the data indicate that human p53 is not a substrate for recombinant ERK1 (Figure 1 ) nor for serum-or TPA-stimulated protein kinase activities in human cell extracts (Figures 1 ± 3) , even though these activities are present in human cell lysates and are able to phosphorylate the murine protein (Figures 1 and 2) . The data suggest that neither MAP kinase, nor any other uncharacterized protein kinase which might be activated in response to the same agents, can P-orthophosphate per 15 cm plate for 3 h as described previously (Milne et al., 1994) . Thirty minutes prior to harvesting, the protein kinase C-speci®c activator TPA was added to a ®nal concentration of 160 ng/ml (b, d and f); an equal volume of DMSO, the solvent for the inhibitor, was added to control (a,c and e). Cells were lysed in 10 mM Tris [pH 7.5], 2 mM EDTA, 0.1 M NaCl, 50 mM NaF, 1% (v/v) IGEPAL, 1 mM benzamidine, 1.9 mg/ml aprotinin, 1 mM leupeptin, and 1 mM pepstatin. p53 was immunoprecipitated and phosphopeptide analysis was carried out using the procedure described by Knippschild et al. (1997) . The identities of known phosphopeptides are indicated in the left-hand panels. The location of the phosphopeptide phosphorylated by MAP kinase in murine cells is indicated in c and d phosphorylate human p53. Moreover, while TPA stimulation of murine ®broblasts gave rise to a specific phosphorylation of the proline rich domain of the murine p53 (Milne et al., 1994, 1996 and Figure 3) , no signi®cant changes in the phosphorylation of human p53 were observed when human ®broblasts or epithelial cells were treated in the same way ( Figure  3 ). (The murine p53 phosphopeptide highlighted in Figure 3c ,d was previously identi®ed as amino acids 60 ± 95 (Milne et al., 1994) , encompassing essentially the entire proline rich domain). Taken together, these ®ndings suggest that either the phosphorylation of murine p53 by the MAP kinase pathway is in some way artifactual or unimportant for p53 function (as it is not in operation in at least one other mammalian species), or that there exist true species-dependent dierences in the signalling mechanisms which regulate p53 function. We favour the latter suggestion for several reasons. For example, the TPA-dependent phosphorylation of murine p53 is highly reproducible and speci®c: i.e. there are no signi®cant changes in the presence or levels of any of the other phosphopeptides following the stimulus. Moreover, the selective phosphorylation of murine but not human p53 by MAP kinase is one example of a growing list of dierences in the modi®cations which occur on the human and murine proteins. For example, DNAactivated protein kinase phosphorylates both human and murine p53 at serine 15 but human p53 is additionally phosphorylated at serine 37 (a site not present in murine p53) while murine p53 which is phosphorylated at a dierent additional site, serine 4 (a site absent from human p53; Lees-Miller et al., 1990 . Human p53 is phosphorylated in cultured cells within the epitope for monoclonal antibody PAb421 (Waterman et al., 1998) but mutation of the homologous residues in murine p53 does not aect the phosphorylation status of the protein in the cell (Milne et al., 1996) . Phosphorylation sites have been tentatively mapped to the DNA binding domain only of murine p53 (Milne et al., 1996) . Also, serine 34 of murine p53 is a substrate for phosphorylation by the Jun N-terminal kinases (JNKs) both in vitro and in UV-irradiated cultured cells (Hu et al., 1997; Milne et al., 1995) . The equivalent residue in human p53 (serine 33) is a substrate for the cyclin H-CDK7-Mat1 complex (Ko et al., 1997) whereas JNK is thought to phosphorylate a residue(s) lying between amino acids 90 and 280 in human p53 (Adler et al., 1997) . Finally, the concept of species-speci®c dierences in p53 phosphorylation has also been highlighted by other researchers for other species. For example, Patschinsky et al. (1992) noted striking qualitative and quantitative dierences in the phosphorylation of murine and rat p53, particularly in the context of transformation by SV40. Similarly, Muller and Scheidtmann (1995) observed that a T Antigen-activated kinase phosphorylates rat p53 in a manner that is dependent on prior phosphorylation by CDK and at a site which is absent in p53 other species. Taken together these independent observations make a strong case for species-speci®c dierences in the modi®cation, and therefore possibly in the regulation, of p53.
Species variance in the modi®cation of p53 has several implications for the regulatory mechanisms which govern p53 function. Firstly, there may be subtle dierences in the routes by which p53 is sensitive to environmental change. For example, it is possible that, in addition to regulation through the p19 ARF pathway, mice have adopted an auxiliary mechanism (the MAP kinase pathway) which contributes to the ability of p53 to sense changes in the growth status. Moreover, while a particular modi®cation site in one species may respond to a speci®c stimulus by a given route, the equivalent site(s) in p53 from other species may respond to dierent, or perhaps related, signalling routes. It is also possible that there could be subtle species-dependent variations in p53 function: appropriate regulatory mechanisms would be required to modulate such functional dierences. Finally, understanding these dierences is likely to be important for several reasons. For example, in the study of animal models for the role of p53 in human cancer it is possible that dierences in the regulation between the species, although perhaps subtle, may have a signi®cant in¯uence on the quality of the p53 response or the outcome of drug administration.
